Business Context and Reporting Period
This Form 8-K was filed by Novus Therapeutics, Inc. (NVUS) on January 16, 2020, reporting events occurring on January 10 and January 15, 2020. The company is a biopharmaceutical firm focused on developing treatments for acute otitis media.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $5.8 million from the cash exercise of warrants.
- Shares Issued: 6,898,224 shares of common stock.
- Exercise Price: $0.715 per share for the exercised warrants, plus an additional $0.125 per share allocated to the issuance of new Private Placement Warrants.
- Placement Agent Fees: 7.0% cash fee, 1.0% management fee, and $85,000 for non-accountable expenses paid to H.C. Wainwright & Co., LLC.
- Placement Agent Warrants: 344,911 warrants granted to the agent at an exercise price of $1.05.
Material Changes and New Agreements
The company entered into Warrant Exercise Agreements with holders of Series A and Series B Warrants issued in May 2019. Holders agreed to exercise their warrants at a reduced price. Concurrently, the company issued new Private Placement Warrants to these holders to purchase up to 6,898,224 shares at an exercise price of $0.72 per share with a 5.5-year term.
Use of Proceeds and Outlook
Management intends to use the net proceeds to fund the ongoing Phase 2a clinical trial for acute otitis media, as well as for working capital and general corporate purposes. The filing does not provide specific revenue, profit, or cash flow metrics for a reporting period, as this is a current report regarding a specific transaction rather than a periodic financial statement.
Investor Verification Checklist
- Verify the closing of the Private Placement Warrants issued on January 14 and January 17, 2020.
- Confirm the exact net proceeds after deducting the 8.0% total cash fees and $85,000 in expenses.
- Review the impact of the 6,898,224 new shares and potential future dilution from the Private Placement Warrants and Placement Agent Warrants.
- Monitor the progress and funding status of the Phase 2a clinical trial for acute otitis media.